Pharming (PHAR) Income from Non-Controlling Interests (2023 - 2025)
Pharming (PHAR) posted Income from Non-Controlling Interests of -$1.1 million for Q4 2025, down 208.74% on a QoQ basis from -$366000.0 in Q3 2025, and up 0.96% year-over-year from -$1.1 million in Q4 2024.
Pharming (PHAR) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Pharming's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$1.1 million for Q4 2025.
- Quarterly Income from Non-Controlling Interests rose 0.96% year-over-year to -$1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.0 million (up 28.26% YoY) and the FY2025 annual result came in at -$313000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests was -$1.1 million for Q4 2025 at Pharming, down from -$366000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$169000.0 in Q1 2025 and bottomed at -$1.1 million in Q4 2024.
- A 3-year average of -$591875.0 and a median of -$339500.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests grew 4.44% — and 2025, when it sank 41.86%.
- Pharming's Income from Non-Controlling Interests stood at -$1.1 million in 2023, then decreased by 4.87% to -$1.1 million in 2024, then increased by 0.96% to -$1.1 million in 2025.
- Business Quant data shows PHAR's Income from Non-Controlling Interests at -$1.1 million in Q4 2025, -$366000.0 in Q3 2025, and -$313000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Pharming | 8.69 Bn | 8.64 Bn | 65.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.13 Mn |
| Sep 30, 2025 | -366,000.00 |
| Jun 30, 2025 | -313,000.00 |
| Mar 31, 2025 | -169,000.00 |
| Dec 31, 2024 | -1.14 Mn |
| Sep 30, 2024 | -258,000.00 |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -270,000.00 |